North America Hypophosphatasia Treatment Market

List of Tables

North America hypophosphatasia treatment market is expected to reach USD 1,362.78 million by 2031, from USD 978.68 million in 2023 growing at the CAGR of 4.7% in the forecast period of 2024 to 2031.

Market Segmentation

North America Hypophosphatasia Treatment Market, By Types (Odontohypophosphatasia, Pseudohypophosphatasia, and Others), Therapy Type (Enzyme Replacement Therapy and Supportive Therapy), Route of Administration (Injectable and Oral), End User (Hospitals, Speciality Clinics, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), Country (U.S., Canada, and Mexico) - Industry Trends and Forecast to 2031

Overview of North America Hypophosphatasia Treatment Market Dynamics:

Drivers
Increasing incidence rate for hypophosphatasia
Continuous increase in clinical trials and pipeline products
Favorable reimbursement policies
Restraints
High cost of treatment
Complex treatment regimen
Opportunities
Increasing adoption of various types of advanced therapy
Initiatives by the government to create awareness
Challenges
Impact of discontinuation of drug treatment and related adverse effect
Genetic variability and disease complexity

Market Players

The key market players for North America hypophosphatasia treatment market are listed below:

AstraZeneca
Pfizer Inc.
Abbott
Novartis AG
AM-Pharma B.V.
Be Biopharma
PuREC
Rallybio
Rampart Bioscience, Inc.
Roivant Sciences Ltd.

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.10 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES
4.3 STRATEGIC DECISIONS
4.4 PATENT ANALYSIS
4.5 PRODUCT SALES BY YEAR

5 NORTH AMERICA HYPOPHOSPHATASIA (HPP) TREATMENT MARKET: REGULATIONS

5.1 U.S. REGULATORY SCENARIO FOR HYPOPHOSPHATASIA (HPP) TREATMENT
5.2 EUROPE REGULATORY SCENARIO FOR HYPOPHOSPHATASIA (HPP) TREATMENT
5.3 INDIA
5.4 MIDDLE EAST AND AFRICA

6 MARKET OVERVIEW

6.1 DRIVERS
- 6.1.1 INCREASING INCIDENCE RATE FOR HYPOPHOSPHATASIA
- 6.1.2 CONTINUOUS INCREASE IN CLINICAL TRIALS AND PIPELINE PRODUCTS
- 6.1.3 FAVOURABLE REIMBURSEMENT POLICIES
6.2 RESTRAINTS
- 6.2.1 HIGH COST OF TREATMENT
- 6.2.2 COMPLEX TREATMENT REGIMEN
6.3 OPPORTUNITIES
- 6.3.1 INCREASING ADOPTION OF VARIOUS TYPES OF ADVANCED THERAPY
- 6.3.2 INITIATIVES BY THE GOVERNMENT TO CREATE AWARENESS
6.4 CHALLENGES
- 6.4.1 IMPACT OF DISCONTINUATION OF DRUG TREATMENT AND RELATED ADVERSE EFFECT
- 6.4.2 GENETIC VARIABILITY AND DISEASE COMPLEXITY

7 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES

7.1 OVERVIEW
7.2 ODONTOHYPOPHOSPHATASIA
7.3 PSEUDOHYPOPHOSPHATASIA
7.4 OTHERS

8 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE

8.1 OVERVIEW
8.2 ENZYME REPLACEMENT THERAPY
8.3 SUPPORTIVE THERAPY

9 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

9.1 OVERVIEW
9.2 INJECTABLE
9.3 ORAL

10 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL

10.1 OVERVIEW
10.2 HOSPITAL PHARMACY
10.3 RETAIL PHARMACY
10.4 ONLINE PHARMACY

11 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER

11.1 OVERVIEW
11.2 HOSPITALS
11.3 SPECIALTY CLINICS
11.4 OTHERS

12 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY REGION

12.1 OVERVIEW
12.2 NORTH AMERICA
- 12.2.1 U.S.
- 12.2.2 CANADA
- 12.2.3 MEXICO

13 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: NORTH AMERICA

14 SWOT ANALYSIS

15 COMPANY PROFILE

15.1 ASTRAZENECA
- 15.1.1 COMPANY SNAPSHOT
- 15.1.2 REVENUE ANALYSIS
- 15.1.3 COMPANY SHARE ANALYSIS
- 15.1.4 PRODUCT PORTFOLIO
- 15.1.5 RECENT DEVELOPMENT
15.2 PFIZER INC.
- 15.2.1 COMPANY SNAPSHOT
- 15.2.2 REVENUE ANALYSIS
- 15.2.3 COMPANY SHARE ANALYSIS
- 15.2.4 PRODUCT PORTFOLIO
- 15.2.5 RECENT DEVELOPMENTS
15.3 ABBOTT
- 15.3.1 COMPANY SNAPSHOT
- 15.3.2 REVENUE ANALYSIS
- 15.3.3 COMPANY SHARE ANALYSIS
- 15.3.4 PRODUCT PORTFOLIO
- 15.3.5 RECENT DEVELOPMENTS
15.4 NOVARTIS AG
- 15.4.1 COMPANY SNAPSHOT
- 15.4.2 REVENUE ANALYSIS
- 15.4.3 COMPANY SHARE ANALYSIS
- 15.4.4 PRODUCT PORTFOLIO
- 15.4.5 RECENT DEVELOPMENT
15.5 AM-PHARMA B.V.
- 15.5.1 COMPANY SNAPSHOT
- 15.5.2 COMPANY SHARE ANALYSIS
- 15.5.3 PRODUCT PORTFOLIO
- 15.5.4 RECENT DEVELOPMENT
15.6 BE BIOPHARMA
- 15.6.1 COMPANY SNAPSHOT
- 15.6.2 PRODUCT PORTFOLIO
- 15.6.3 RECENT DEVELOPMENT
15.7 PUREC.
- 15.7.1 COMPANY SNAPSHOT
- 15.7.2 PRODUCT PORTFOLIO
- 15.7.3 RECENT DEVELOPMENT
15.8 RALLYBIO
- 15.8.1 COMPANY SNAPSHOT
- 15.8.2 PRODUCT PORTFOLIO
- 15.8.3 RECENT DEVELOPMENTS
15.9 RAMPART BIOSCIENCE, INC.
- 15.9.1 COMPANY SNAPSHOT
- 15.9.2 PRODUCT PORTFOLIO
- 15.9.3 RECENT DEVELOPMENT
15.10 ROIVANT SCIENCES LTD.
- 15.10.1 COMPANY SNAPSHOT
- 15.10.2 PRODUCT PORTFOLIO
- 15.10.3 RECENT DEVELOPMENT

16 QUESTIONNAIRE

17 RELATED REPORTS

LIST OF TABLES

TABLE 1 VARIOUS ASPECTS OF HYPOPHOSPHATASIA (HPP)
TABLE 2 TARGETED TREATMENT OF HYPOPHOSPHATASIA
TABLE 3 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND)
TABLE 4 NORTH AMERICA ODONTOPHOSPHATASIA IN HYPOPHOSPHATASIA TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 5 NORTH AMERICA PSEUDOPHOSPHATASIA IN HYPOPHOSPHATASIA TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 6 NORTH AMERICA OTHERS IN HYPOPHOSPHATASIA TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 7 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND)
TABLE 8 NORTH AMERICA ENZYME REPLACEMENT THERAPY IN HYPOPHOSPHATASIA TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 9 NORTH AMERICA SUPPORTIVE THERAPY IN HYPOPHOSPHATASIA TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 10 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 11 NORTH AMERICA INJECTABLE IN HYPOPHOSPHATASIA TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 12 NORTH AMERICA ORAL IN HYPOPHOSPHATASIA TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 13 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND)
TABLE 14 NORTH AMERICA HOSPITAL PHARMACY IN HYPOPHOSPHATASIA TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 15 NORTH AMERICA RETAIL PHARMACY IN HYPOPHOSPHATASIA TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 16 NORTH AMERICA ONLINE PHARMACY IN HYPOPHOSPHATASIA TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 17 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY END-USER, 2022-2031 (USD THOUSAND)
TABLE 18 NORTH AMERICA HOSPITALS IN HYPOPHOSPHATASIA TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 19 NORTH AMERICA SPECIALTY CLINICS IN HYPOPHOSPHATASIA TREATMENTMARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 20 NORTH AMERICA OTHERS IN HYPOPHOSPHATASIA TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 21 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY REGION, 2022-2031 (USD THOUSAND)
TABLE 22 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD THOUSAND )
TABLE 23 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND )
TABLE 24 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND )
TABLE 25 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND )
TABLE 26 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND )
TABLE 27 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND )
TABLE 28 U.S. HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND )
TABLE 29 U.S. HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND )
TABLE 30 U.S. HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND )
TABLE 31 U.S. HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND )
TABLE 32 U.S. HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND )
TABLE 33 CANADA HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND )
TABLE 34 CANADA HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND )
TABLE 35 CANADA HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND)
TABLE 36 CANADA HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND )
TABLE 37 CANADA HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND )
TABLE 38 MEXICO HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES, 2022-2031 (USD THOUSAND )
TABLE 39 MEXICO HYPOPHOSPHATASIA TREATMENT MARKET, BY THERAPY TYPE, 2022-2031 (USD THOUSAND )
TABLE 40 MEXICO HYPOPHOSPHATASIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD THOUSAND )
TABLE 41 MEXICO HYPOPHOSPHATASIA TREATMENT MARKET, BY END USER, 2022-2031 (USD THOUSAND )
TABLE 42 MEXICO HYPOPHOSPHATASIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD THOUSAND )

LIST OF FIGURES

FIGURE 1 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: SEGMENTATION
FIGURE 11 SEGMENTS COMPRISE THE NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET, BY TYPES
FIGURE 12 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET : EXECUTIVE SUMMARY
FIGURE 13 INCREASING DIAGNOSIS FOR HYPOPHOSPHATASIA IS DRIVING THE GROWTH OF THE NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET FROM 2024 TO 2031
FIGURE 14 THE TYPES SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET IN 2024 AND 2031
FIGURE 15 DRIVERS, RESTRIANTS, OPPORTUNITIES, AND CHALLENGES OF HYPOPHOSPHATASIA TREATMENT MARKET
FIGURE 16 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: BY TYPES, 2023
FIGURE 17 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: BY TYPES, 2024-2031 (USD THOUSAND)
FIGURE 18 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: BY TYPES, CAGR (2024-2031)
FIGURE 19 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: BY TYPES, LIFELINE CURVE
FIGURE 20 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: BY THEREPY TYPE, 2023
FIGURE 21 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: BY THEREPY TYPE, 2024-2031 (USD THOUSAND)
FIGURE 22 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: BY THEREPY TYPE, CAGR (2024-2031)
FIGURE 23 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: BY THEREPY TYPE, LIFELINE CURVE
FIGURE 24 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023
FIGURE 25 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD THOUSAND)
FIGURE 26 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)
FIGURE 27 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 28 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 29 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD THOUSAND)
FIGURE 30 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 31 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 32 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: BY END USER, 2023
FIGURE 33 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: BY END USER, 2024-2031 (USD THOUSAND)
FIGURE 34 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: BY END USER, CAGR (2024-2031)
FIGURE 35 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 36 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: SNAPSHOT (2023)
FIGURE 37 NORTH AMERICA HYPOPHOSPHATASIA TREATMENT MARKET: COMPANY SHARE 2023 (%)